Investor

Thomas Ebeling

Earlier in his career, Thomas served as CEO of Novartis Pharmaceuticals, during which their pharmaceuticals division more than doubled its revenues. Mr. Ebeling has also been a member of the supervisory board for Bayer AG, Lonza, and currently serves as the Chairman of GfK’s Board of Directors. He is also on the Board of Directors of Qiagen, Cullinan, Orna, and is a member of the Advisory Board of the UBS Oncology Impact Fund by MPM Capital. Most recently, he served as Chief Executive Officer of ProSiebenSat.1—a mass media group in Germany.
‍